Clinical Trials Logo

Primary IgA Nephropathy clinical trials

View clinical trials related to Primary IgA Nephropathy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04541043 Active, not recruiting - Clinical trials for Primary IgA Nephropathy

Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)

Nefigard-OLE
Start date: November 14, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef-301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon.

NCT ID: NCT04014335 Active, not recruiting - Clinical trials for Primary IgA Nephropathy

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

Start date: December 4, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of IONIS-FB-LRx, an antisense inhibitor of complement factor B messenger ribonucleic acid (CFB mRNA), and to evaluate the effect of IONIS-FB-LRx on plasma factor B (FB) levels and serum AH50, CH50 activity in participants with primary immunoglobulin A (IgA) nephropathy.